[
  {
    "ts": null,
    "headline": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
    "summary": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
    "url": "https://finnhub.io/api/news?id=d7ed624044a165ef9e4f90ed98a5ca13b641b58b3a3ee802a806a6969c4982fc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744377180,
      "headline": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
      "id": 134146899,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Pharma Tariffs Are Coming. Investors Underestimate the Risk.",
      "url": "https://finnhub.io/api/news?id=d7ed624044a165ef9e4f90ed98a5ca13b641b58b3a3ee802a806a6969c4982fc"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis",
    "summary": "BOSTON, April 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner International Award \"for pioneering research into the cellular and molecular mechanisms underlying the genetic disease cystic fibrosis, leading to the development of transformative drug therapies based on these mechanisms, thereby improving and saving countless lives.\" Negulescu shares the award with Michael",
    "url": "https://finnhub.io/api/news?id=d248136013819704cbb32e3b65705782d3e3603dac2c09fa36a6a6f91a6120db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744363800,
      "headline": "Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis",
      "id": 133880851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, April 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner International Award \"for pioneering research into the cellular and molecular mechanisms underlying the genetic disease cystic fibrosis, leading to the development of transformative drug therapies based on these mechanisms, thereby improving and saving countless lives.\" Negulescu shares the award with Michael",
      "url": "https://finnhub.io/api/news?id=d248136013819704cbb32e3b65705782d3e3603dac2c09fa36a6a6f91a6120db"
    }
  },
  {
    "ts": null,
    "headline": "Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?",
    "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success.  It recently won approval for a non-opioid pain treatment that could be a game-changer for both patients and the company down the road.  Of course, Vertex's success didn't happen overnight -- and the company even had to quickly shift focus after its initial drug, a hepatitis C treatment, didn't deliver lasting growth.",
    "url": "https://finnhub.io/api/news?id=2a5d53faa8a7fdd10c448b827119f1600512fccecd3433cd1fff5b3c31c88cbd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744357500,
      "headline": "Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?",
      "id": 133880852,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success.  It recently won approval for a non-opioid pain treatment that could be a game-changer for both patients and the company down the road.  Of course, Vertex's success didn't happen overnight -- and the company even had to quickly shift focus after its initial drug, a hepatitis C treatment, didn't deliver lasting growth.",
      "url": "https://finnhub.io/api/news?id=2a5d53faa8a7fdd10c448b827119f1600512fccecd3433cd1fff5b3c31c88cbd"
    }
  },
  {
    "ts": null,
    "headline": "How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs",
    "summary": "How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs",
    "url": "https://finnhub.io/api/news?id=9468a60956e0b803a1b9509f578755987131d5608df73eca287da74491f3b31f",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744349400,
      "headline": "How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs",
      "id": 133885756,
      "image": "",
      "related": "VRTX",
      "source": "DowJones",
      "summary": "How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs",
      "url": "https://finnhub.io/api/news?id=9468a60956e0b803a1b9509f578755987131d5608df73eca287da74491f3b31f"
    }
  }
]